Neuronetics (STIM) director Megan Rosengarten granted 30,000 RSUs, now holds 170,890 shares

Rhea-AI Filing Summary

Neuronetics, Inc. director Megan Rosengarten reported receiving an award of 30,000 restricted stock units of common stock. The RSU grant is a form of equity compensation and carries no cash exercise price.

The award vests on the earlier of May 28, 2027, or her Board-approved separation of service or a change in control of Neuronetics, in each case requiring her continuous service through that date. After this grant, she holds 170,890 shares and RSUs of Neuronetics common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rosengarten Megan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,000	$0.00	--

Holdings After Transaction: Common Stock — 170,890 shares (Direct, null)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Key Figures

RSU grant size: 30,000 units Shares after transaction: 170,890 shares/units RSU grant price: $0.0000 per unit +1 more

4 metrics

RSU grant size 30,000 units Restricted stock units of common stock granted to director

Shares after transaction 170,890 shares/units Direct holdings following RSU award

RSU grant price $0.0000 per unit Reported transaction price for the RSU award

RSU vesting date May 28, 2027 Latest possible vesting date, subject to earlier events

Key Terms

restricted stock unit ("RSU") award, change in control, continuous service, contingent right

4 terms

restricted stock unit ("RSU") award financial

"Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027..."

change in control financial

"...Board-approved separation of service from the Issuer or change in control of the Issuer..."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"...in each case subject to continuous service of the Reporting Person through such date."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosengarten Megan

(Last) (First) (Middle)

C/O NEURONETICS, INC

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		30,000(1)	A	$0(2)	170,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Francis Brown, as Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Neuronetics (STIM) director Megan Rosengarten report in this Form 4?

She reported an equity compensation grant of 30,000 restricted stock units of Neuronetics common stock. These RSUs were awarded at no cash cost and increase her direct holdings to 170,890 shares and units after the transaction, according to the filing’s ownership table.

When do Megan Rosengarten’s 30,000 Neuronetics (STIM) RSUs vest?

The 30,000 RSUs vest on the earlier of May 28, 2027, or her Board-approved separation of service or a change in control of Neuronetics. Vesting in each case is conditioned on her continuous service with the company through the applicable date.

How many Neuronetics (STIM) shares does Megan Rosengarten hold after this RSU grant?

After the RSU award, the filing shows Megan Rosengarten with 170,890 shares and units of Neuronetics common stock held directly. This figure reflects her position following the 30,000 restricted stock units reported in the current Form 4 transaction.

What does each Neuronetics (STIM) RSU granted to Megan Rosengarten represent?

Each RSU represents a contingent right to receive one share of Neuronetics common stock upon vesting. The award therefore corresponds to up to 30,000 shares, subject to the vesting conditions tied to service, separation events, or a change in control of the company.

Was Megan Rosengarten’s Neuronetics (STIM) RSU award a market purchase or sale?

No, the Form 4 characterizes the transaction as a grant or award acquisition, coded “A.” The 30,000 RSUs were issued as equity compensation at a reported price of $0.0000 per unit, rather than being bought or sold in the open market.